🇺🇸 Viatris Inc.
Forum topic · VTRS · Company page: financials, ownership and filings
Join the discussion on Viatris Inc.
Loading…
Results announced on 5 November 2026
Viatris Inc. announced results on 5 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $3.7 billion (level with a year earlier).
Mutual funds: 601 funds hold $8.5 billion
601 mutual funds in 3 countries hold shares of Viatris Inc. worth $8.5 billion, about 45.1% of the company (funds' newest reports, up to 31 October 2026).
Since their previous reports 262 funds added shares and 238 sold; on balance they bought $721 million. Share splits are not counted as trading.
Product recall: Telmisartan and Amlodipine, Tablets, USP, 40mg/5 mg, 30-count Bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA,
Drugs (FDA) published a recall by Viatris, Inc. on 1 October 2026: Telmisartan and Amlodipine, Tablets, USP, 40mg/5 mg, 30-count Bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA, Made in India, NDC 0378-1075-93..
Reason: Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications
Units affected: 21,620.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.